Fulcrum Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.18
- Today's High:
- $5.44
- Open Price:
- $5.27
- 52W Low:
- $2.25
- 52W High:
- $15
- Prev. Close:
- $5.33
- Volume:
- 436997
Company Statistics
- Market Cap.:
- $353.63 million
- Book Value:
- 4.455
- Revenue TTM:
- $3.04 million
- Operating Margin TTM:
- -3520.64%
- Gross Profit TTM:
- $-70440000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.02%
- Return on Equity TTM:
- -45.13%
Company Profile
Fulcrum Therapeutics Inc had its IPO on 2019-07-18 under the ticker symbol FULC.
The company operates in the Healthcare sector and Biotechnology industry. Fulcrum Therapeutics Inc has a staff strength of 89 employees.
Stock update
Shares of Fulcrum Therapeutics Inc opened at $5.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.18 - $5.44, and closed at $5.22.
This is a -2.06% slip from the previous day's closing price.
A total volume of 436,997 shares were traded at the close of the day’s session.
In the last one week, shares of Fulcrum Therapeutics Inc have slipped by -8.74%.
Fulcrum Therapeutics Inc's Key Ratios
Fulcrum Therapeutics Inc has a market cap of $353.63 million, indicating a price to book ratio of 1.2789 and a price to sales ratio of 26.6208.
In the last 12-months Fulcrum Therapeutics Inc’s revenue was $3.04 million with a gross profit of $-70440000 and an EBITDA of $-104798000. The EBITDA ratio measures Fulcrum Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fulcrum Therapeutics Inc’s operating margin was -3520.64% while its return on assets stood at -27.02% with a return of equity of -45.13%.
In Q2, Fulcrum Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 53.2%.
Fulcrum Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.79 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fulcrum Therapeutics Inc’s profitability.
Fulcrum Therapeutics Inc stock is trading at a EV to sales ratio of 7.0377 and a EV to EBITDA ratio of -0.7166. Its price to sales ratio in the trailing 12-months stood at 26.6208.
Fulcrum Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $300.33 million
- Total Liabilities
- $14.80 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $195000
- Dividend Payout Ratio
- 0%
Fulcrum Therapeutics Inc ended 2024 with $300.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $300.33 million while shareholder equity stood at $275.43 million.
Fulcrum Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $14.80 million in other current liabilities, 62000.00 in common stock, $-460900000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.97 million and cash and short-term investments were $278.16 million. The company’s total short-term debt was $2,507,000 while long-term debt stood at $0.
Fulcrum Therapeutics Inc’s total current assets stands at $282.95 million while long-term investments were $0 and short-term investments were $244.20 million. Its net receivables were $2.07 million compared to accounts payable of $3.91 million and inventory worth $-1414000.00.
In 2024, Fulcrum Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $195000.
Comparatively, Fulcrum Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.22
- 52-Week High
- $15
- 52-Week Low
- $2.25
- Analyst Target Price
- $10.57
Fulcrum Therapeutics Inc stock is currently trading at $5.22 per share. It touched a 52-week high of $15 and a 52-week low of $15. Analysts tracking the stock have a 12-month average target price of $10.57.
Its 50-day moving average was $4.36 and 200-day moving average was $5.6 The short ratio stood at 4.27 indicating a short percent outstanding of 0%.
Around 158.3% of the company’s stock are held by insiders while 9873.5% are held by institutions.
Frequently Asked Questions About Fulcrum Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.